You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Send a link to this page to your friends and colleagues.
An agreement to develop and market orally administered insulin products, which might total as much as $238 million, has been signed by GlaxoSmithKline of London and Nobex Corporation of Research Triangle Park, North Carolina.
Under the terms of the agreement, GlaxoSmithKline will pay a fee up-front to Nobex, with additional payments related to product development, manufacturing and marketing.
The first product, which is in phase 1 and 2 clinical trials, is a modified oral insulin designed to control post-meal blood-glucose levels. The process uses a technology that allows the insulin to be rapidly absorbed into the bloodstream. "Nobex oral insulin is absorbed across the intestinal wall and follows a similar pathway as insulin normally released by the pancreas," the companies said in a news release.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.